Independent, Comparative Evaluation by Leading Research Centers in Germany and Portugal Indicates Significant Biopreservation Advantages of Serum-Free, Pre-Formulated CryoStor
BOTHELL, Wash., March 10 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary cGMP hypothermic storage and cryopreservation media products for cells, tissue, and organs, today announced that an independent European comparison of the Company's CryoStor pre-formulated serum-free and protein-free biopreservation media against traditional in-house formulated culture media/serum/DMSO showed CryoStor offers a significant cryopreservation process improvement and better cellular outcomes. Compared to media/serum/DMSO, CryoStor enabled enhanced post-thaw cell membrane integrity and a full recovery of metabolic activity and differentiation capacity within 24 hours after thawing.
The study, titled "Cryopreservation of Adherent Cells: Strategies to Improve Cell Viability and Function after Thawing," was published in the January 2009 online issue of Tissue Engineering Part C. This reports the results of experiments conducted by research teams at the Fraunhofer IBMT in St. Ingbert/Sulzbach, Germany and IBET/ITQB-UNL in Oeiras, Portugal.
The study findings also confirm that despite improved cell recovery immediately after thawing for media/serum/DMSO cryopreserved cells beneath alginate, up to 50 percent cell death still occurred within 24 hours post-thawing. The authors agreed with other published data describing post-thaw survival overestimates, and suggest that the decrease in cell viability might be related to sequential apoptotic and necrotic processes not evident immediately subsequent to thawing. This supports very early BioLife research and discoveries of the phenomena of preservation-induced, delayed onset cell death.
Mike Rice, BioLife's chairma
|SOURCE BioLife Solutions, Inc.|
Copyright©2009 PR Newswire.
All rights reserved